Zai Lab Limited (ZLAB) Key Metrics

NASDAQ: ZLABValuation, returns, debt and efficiency ratios over 10 years.

ZLAB valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$2.60B
Enterprise value
$2.65B
P/E (TTM)
—
Forward P/E
—
PEG ratio
—
Price / sales
5.8
10-yr median 13.7
Price / book
4.9
10-yr median 3.8
EV / EBITDA
—
Dividend yield
—
Beta
0.72

ZLAB key metrics, 2016–2025

Fiscal year ended December 31, 2025 · U.S. dollars

ZLAB valuation Price multiples at each fiscal year-end price.

Price / sales−35.4%
4.2
2025 · hover or tap a bar for each year
2019: 206.22020: 214.7 (+4.1%)2021: 40.5 (−81.1%)2022: 13.7 (−66.2%)2023: 9.9 (−27.6%)2024: 6.5 (−34.4%)2025: 4.2 (−35.4%)
20162025
Price / book−12.4%
2.7
2025 · hover or tap a bar for each year
2018: 4.92019: 9.1 (+86.7%)2020: 9.0 (−1.1%)2021: 4.2 (−52.9%)2022: 2.8 (−33.6%)2023: 3.3 (+17.9%)2024: 3.1 (−7.1%)2025: 2.7 (−12.4%)
20162025
Free cash flow yield+2.2 pts
−8.5%
2025 · hover or tap a bar for each year
2018: −8.8%2019: −7.7% (+1.1 pts)2020: −2.2% (+5.5 pts)2021: −9.7% (−7.6 pts)2022: −13.3% (−3.6 pts)2023: −7.8% (+5.5 pts)2024: −10.7% (−2.8 pts)2025: −8.5% (+2.2 pts)
20162025

ZLAB valuation history

Fiscal year-endToday10-year median

ZLAB returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

ZLAB debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

ZLAB cash returned to shareholders

DividendsBuybacksFree cash flow

ZLAB price vs earnings per share

Share price at year-endEPS (right axis)

ZLAB key metrics

2016–2025
Zai Lab Limited key metrics by fiscal year
2025202420232022202120202019201820172016
Valuation
Market capitalization$1.93B$2.59B$2.64B$2.94B$5.84B$10.51B$2.68B$1.22B——
Enterprise value$1.47B$1.97B$1.85B$1.95B$4.45B$9.34B$2.42B$961.9M——
Price / sales4.26.59.913.740.5214.7206.2———
Price / book2.73.13.32.84.29.09.14.9——
EV / sales3.24.96.99.130.8190.8186.6———
Earnings yield−9.1%−9.9%−12.7%−15.1%−12.1%−2.6%−6.8%−11.4%——
Free cash flow yield−8.5%−10.7%−7.8%−13.3%−9.7%−2.2%−7.7%−8.8%——
Dividend yield———0.5%——————
Shareholder yield (dividends + buybacks)——0.3%0.8%0.1%—0.0%0.0%——
Share price at fiscal year-end$17.64$26.19$27.33$30.70$62.85$135.34$41.59$23.22$21.23—
Per share
Revenue per share$4.20$4.03$2.76$2.24$1.55$0.63$0.20$0.00——
Earnings per share−$1.60−$2.60−$3.46−$4.63−$7.58−$3.46−$2.85−$2.64——
Operating cash flow per share−$1.38−$2.17−$2.05−$3.84−$5.91−$2.78−$2.97−$1.85——
Free cash flow per share−$1.50−$2.79−$2.14−$4.10−$6.11−$2.92−$3.20−$2.05——
Cash per share$6.30$7.88$8.34$10.53$15.15$15.28$4.29$5.00——
Book value per share$6.53$8.50$8.24$10.91$14.84$15.06$4.58$4.77——
Tangible book value per share$5.84$7.90$8.07$10.83$14.74$14.93$4.44$4.77——
Dividends per share———$0.17——————
Capex per share$0.12$0.62$0.09$0.26$0.20$0.14$0.24$0.19——
Debt per share$2.05$1.55$0.16$0.21$0.17$0.24$0.34$0.07——
Shares outstanding109.5M98.9M96.6M95.8M93.0M77.7M64.4M52.6M——
Change in shares outstanding+10.7%+2.4%+0.9%+3.0%+19.7%+20.7%+22.4%———
Returns & profitability
Return on equity (ROE)−22.6%−31.4%−36.3%−36.6%−55.3%−36.7%−67.2%−57.2%−54.9%—
Return on invested capital (ROIC)−76.0%−203.1%−929.1%—————−3.6%—
Return on assets (ROA)−14.9%−23.1%−29.7%−31.3%−48.5%−32.5%−55.8%−50.4%−29.8%−72.9%
Return on tangible assets−16.0%−22.8%−32.8%−36.6%−44.0%−20.9%−52.9%−46.1%−20.2%−42.2%
Free cash flow margin−35.7%−69.3%−77.5%−182.6%−393.7%−463.1%————
Financial health
Total debt$224.3M$153.5M$15.2M$20.4M$15.5M$18.6M$21.8M$3.6M$2.39B—
Cash & short-term investments$689.6M$779.7M$806.5M$1.01B$1.41B$1.19B$275.9M$263.3M$229.7M$83.9M
Net debt−$465.3M−$626.2M−$791.3M−$988.1M−$1.39B−$1.17B−$254.2M−$259.7M$2.16B−$83.9M
Debt / equity0.310.180.020.020.010.020.070.0110.18—
Debt / assets0.190.130.010.020.010.010.060.019.59—
Current ratio2.453.514.638.047.7812.406.275.5119.1116.25
Quick ratio2.273.384.417.817.6812.276.145.5119.1116.25
Interest coverage-42.9-125.2-25.1-27.7-209.0—-693.5—-40.9-37.9
Working capital$603.1M$751.1M$736.5M$984.5M$1.31B$1.12B$245.8M$220.3M$218.5M$78.9M
Invested capital$250.2M$214.7M$4.8M$57.5M−$13.6M$1.2M$40.5M−$8.6M$2.40B−$135.5M
Tangible asset value$639.4M$782.0M$779.7M$1.04B$1.37B$1.16B$285.9M$250.8M$235.2M−$51.6M
Net current asset value$562.4M$705.6M$699.4M$949.8M$1.27B$1.09B$232.0M$218.2M$216.2M−$56.4M
Graham net-net per share$3.19$5.27$6.60$9.25$13.22$13.76$3.44$4.04——
Capital allocation
Dividends paid———$16.1M——————
Share buybacks (net)——$8.8M$7.6M$4.3M—$0$0$0$0
Capex / revenue2.9%15.4%3.2%11.6%13.1%21.8%117.4%7,815.9%——
Capex / depreciation0.895.190.943.042.922.304.056.1316.6411.20
Stock-based compensation / revenue14.3%17.7%29.9%28.5%28.2%50.7%156.3%9,447.2%——
R&D / revenue48.0%58.8%99.7%133.2%397.3%454.9%1,095.3%92,913.2%——
SG&A / revenue60.3%74.9%105.6%120.4%151.6%227.4%540.7%16,667.1%——
Efficiency
Days sales outstanding77.570.877.987.775.833.454.5253.8——
Days of inventory on hand109.5104.5145.6124.7112.114.6292.532.0——
Days payables outstanding231.6264.0340.9473.7659.665.02,925.4194,263.4——
Cash conversion cycle (days)-44.6-88.7-117.3-261.3-471.6-17.0-2,578.3-193,977.7——
Receivables turnover4.715.164.684.164.8110.936.691.44——
Payables turnover1.581.381.070.770.555.610.120.000.000.00
Inventory turnover3.333.492.512.933.2625.011.2511.41——
Asset turnover0.390.360.240.150.100.060.040.000.000.00
Average receivables$97.8M$77.4M$57.0M$51.7M$30.0M$4.5M$1.9M$90,000——
Average payables$121.3M$106.9M$89.5M$96.1M$94.4M$42.7M$30.0M$23.2M$4.7M$988,196
Average inventory$57.3M$42.4M$38.2M$25.3M$16.0M$9.6M$3.0M$3,822——
Intangibles / total assets6.5%5.0%1.6%0.7%0.6%0.7%2.5%0.1%0.0%0.0%

Computed from ZLAB's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

ZLAB valuation and financial ratios

Zai Lab earned a return on equity of −22.6% and a return on invested capital of −76.0% in fiscal 2025. It ended the year with $224.3 million of debt and $689.6 million in cash and short-term investments, a net cash position of $465.3 million.

See the ZLAB income statement, the ZLAB chart for price history, or the ZLAB stock overview for the latest quote and news.

ZLAB key metrics FAQ

What is Zai Lab's return on equity?

Zai Lab's return on equity (ROE) was −22.6% in fiscal 2025: net income of -$175.5 million on average shareholders' equity of $778.2 million.

What is Zai Lab's ROIC?

Zai Lab's return on invested capital was −76.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.

How much debt does Zai Lab have?

Zai Lab had total debt of $224.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.31 and more cash than debt.

What is Zai Lab's free cash flow yield?

Zai Lab generated -$164.2 million of free cash flow in fiscal 2025, a free cash flow yield of −8.5% on its market value at year-end ($1.9 billion).

What is Zai Lab's current ratio?

Zai Lab's current ratio was 2.45 at the end of fiscal 2025: current assets were 2.45 times current liabilities.

Biotechnology key metrics